PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
1.52 - 1.58
1.19 - 3.37
354.5K / 984.1K (Avg.)
-1.64 | -0.94
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
56.67%
Revenue growth at 50-75% of CSIQ's 86.66%. Martin Whitman would worry about competitiveness or product relevance.
56.16%
Gross profit growth 1.25-1.5x CSIQ's 50.49%. Bruce Berkowitz would see if strategic sourcing or brand premium explains outperformance.
197.71%
EBIT growth above 1.5x CSIQ's 39.38%. David Dodd would confirm if core operations or niche positioning yield superior profitability.
482.57%
Operating income growth above 1.5x CSIQ's 53.97%. David Dodd would confirm if consistent cost or pricing advantages drive this outperformance.
36.18%
Net income growth at 75-90% of CSIQ's 43.41%. Bill Ackman would press for improvements to catch or surpass competitor performance.
-48.15%
Negative EPS growth while CSIQ is at 42.00%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-50.00%
Negative diluted EPS growth while CSIQ is at 40.82%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
4.18%
Share count expansion well above CSIQ's 0.18%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
-2.13%
Reduced diluted shares while CSIQ is at 1.19%. Joel Greenblatt would see a relative advantage if the competitor is diluting more.
No Data
No Data available this quarter, please select a different quarter.
2691.15%
OCF growth of 2691.15% while CSIQ is zero. Bruce Berkowitz would see if small gains can expand into a larger competitive lead.
166.65%
FCF growth of 166.65% while CSIQ is zero. Bruce Berkowitz would see if modest improvements in free cash can accelerate further.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
419.70%
3Y revenue/share CAGR at 50-75% of CSIQ's 602.07%. Martin Whitman would question if the firm lags behind competitor innovations.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
764.13%
3Y OCF/share CAGR of 764.13% while CSIQ is zero. Bruce Berkowitz might see if small gains can expand into a broader advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
48.48%
Below 50% of CSIQ's 6117.25%. Michael Burry suspects a steep short-term disadvantage in bottom-line expansion.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
106.84%
Below 50% of CSIQ's 711.90%. Michael Burry suspects a serious short-term disadvantage in building book value.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
6.20%
AR growth is negative/stable vs. CSIQ's 92.71%, indicating tighter credit discipline. David Dodd confirms it doesn't hamper actual sales.
-9.01%
Inventory is declining while CSIQ stands at 34.11%. Joel Greenblatt sees potential cost and margin benefits if sales hold up.
6.77%
Asset growth well under 50% of CSIQ's 24.45%. Michael Burry sees the competitor as far more aggressive in building resources or capacity.
-0.99%
We have a declining book value while CSIQ shows 7.49%. Joel Greenblatt sees a fundamental disadvantage in net worth creation vs. the competitor.
7.58%
Debt shrinking faster vs. CSIQ's 18.52%. David Dodd sees a safer balance sheet if it doesn't impair future growth.
20.39%
R&D dropping or stable vs. CSIQ's 81.89%. David Dodd sees near-term margin benefits if the product pipeline is already strong.
6.07%
SG&A declining or stable vs. CSIQ's 44.11%. David Dodd sees better overhead efficiency if it doesn't hamper revenue.